TrikenolAcne-prone skin treatment.
Bacterial proliferation inhibition,anti-irritant, sebum regulation and
keratolytic effects
Seboregulating
provitalgroup.com
Technical specifications
Trikenol 75800
PROPERTIES Inhibition of bacterial proliferation. Anti-irritant. Anti-seborrhea. Keratolytic. Comedolytic
ACTIVE MOLECULES TriketonesSalicylic derivatives
APPEARANCE LiquidColor: yellow - dark yellow
SOLUBILITY Soluble in surfactants mixture and in hydroalcoholic solutions
RECOMMENDED 0.20 % Oily skinDOSE 0.80 % Acne-prone skin
Formulation
Oily skin tonic
A
B
C
D
% (w/w)
78.8010.002.003.00
0.80
0.40
5.00
INCI / PCPC
Aqua (Water)Alcohol Denat.GlycerinPropylene Glycol
TRIKENOL
PPG-26-Butheth-26, PEG-40Hydrogenated Castor Oil
Hamamelis extract
Trikenol
Synergic complex containing Manukaconcentrate and Willow extract. Thisproduct is designed for acne proneskin treatment; it reduces sebumproduction, irritation and acts as acomedolytic.
Trikenol is a synergic blenddesigned as an activecompound that improves thehealth of oily, acne-prone skin.
Treatment of oily, acne-proneskin requires concomitantreduction of the involvedmicrobial flora, sebumproduction and irritation, andnormalization of thedesquamation process in thestratum corneum.
Features and benefits
In Vitro
Inhibition of bacterial proliferationStudy of activity against Propionibacterium acnes andStaphylococcus aureus.
Propionibacterium acnes Staphylococcus aureus
MIC SI
0.195% 0.097%
MIC SI
0.78% 0.195%
* SI= Strong Inhibition (a concentration that sufficiently reduces bacterialpopulation).
Trikenol is a bactericide and fungicide active ingredient,useful to treat oily, acne-prone skin.
Assay on primary culture of human keratinocytes.
* SA=Acetyl Salicylic Acid as the positive control.
Willow extract inhibits cyclooxygenase by 43.45%.
0
10
20
30
40
50
60
43.45
70
49.89
63.96
Willowextract0.1%
SA 0.1mM SA 1mM
Anti-irritant activity
Toxicological information
This product has been evaluated according to theavailable toxicological information, based on safetyassays and bibliographical data. These data allowthe conclusion that using this ingredient, under thenormal conditions for the use of cosmetics and atthe recommended concentrations, is free of risks.
Willow
Manuka
In Vivo
Method28 volunteers; daily application of a gel containing 0.8%Trikenol vs placebo; measurements after28 and 56 days.
1. Evaluation of toleranceA dermatologist classified Trikenol as well tolerated bythe skin.
3. Sebum-regulatory effect
Reduction in the amount of sebum (expressed as %) after 28 and 56days of treatment.
4. Self-evaluation of the cosmeticproperties and perceived efficacyTrikenol: good skin tolerability and positive evaluation ofits cosmetic properties by the volunteers.
TrikenolPlacebo
Sebum regulation
Healthier No sheen
Smooth and soft Moisturizing
Cosmetic self evaluation
Sebum index (S) TRIKENOL
Results T28 -9.0
Results T56 -30.3
18.6 -27.6
2.5 -32.8
Placebo Difference
Cosmetic applications
Acne prone skin treatment:
Lotions tonics and emulsions
Reduces the numberof blackheads, thus enhancingthe skin appearance
0
20
40
60
80
100
100%Comedolytic
response
Trikenol Placebo
% Comedolytic response
-25
-20
-15
-10
% -5
0
12.33
Trikenol (T) Placebo (P) Difference (T-P)
5
10
15
-9.35
-21.68
Average variation of the nº of blackheads (%)
2. Evaluation of the comedolyticresponse